An International Consensus Practical Guide on Left Atrial Appendage Closure for the Non-implanting Physician: Executive Summary

Abstract

Many patients with atrial fibrillation (AF) who are in need of stroke prevention are not treated with oral anticoagulation or discontinue treatment shortly after its initiation. Despite the availability of direct oral anticoagulants (DOACs), such undertreatment has improved somewhat but is still evident. This is due to continued risks of bleeding events or ischemic strokes while on DOAC, poor treatment compliance, or aversion to anticoagulant therapy. Because of significant improvements in procedural safety over the years left atrial appendage closure (LAAC), using a catheter-based, device implantation approach, is increasingly favored for the prevention of thromboembolic events in AF patients who cannot have long-term oral anticoagulation. This article is an executive summary of a practical guide recently published by an international expert consensus group, which introduces the LAAC devices and briefly explains the implantation technique. The indications and device follow-up are more comprehensively described. This practical guide, aligned with published guideline/guidance, is aimed at those non-implanting physicians who may need to refer patients for consideration of LAAC.

Keywords

anticoagulation - atrial fibrillation - bleeding - left atrial appendage closure - left atrial appendage occlusion - stroke - prevention

The review process for this paper was fully handled by Christian Weber, Editor in Chief.

Publikationsverlauf

Eingereicht: 12. November 2024

Angenommen: 14. November 2024

Artikel online veröffentlicht:
10. Dezember 2024

• References

• 1 Linz D, Gawalko M, Betz K. et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur 2024; 37: 100786
• 2 Krijthe BP, Kunst A, Benjamin EJ. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34 (35) 2746-2751
• 3 Chao TF, Potpara TS, Lip GYH. Atrial fibrillation: stroke prevention. Lancet Reg Health Eur 2024; 37: 100797
• 4 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146 (12) 857-867
• 5 Ruff CT, Giugliano RP, Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
• 6 Ray WA, Chung CP, Stein CM. et al. Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation. JAMA 2021; 326 (23) 2395-2404
• 7 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF Registry Phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
• 8 Marijon E, Le Heuzey JY, Connolly S. et al; RE-LY Investigators. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation 2013; 128 (20) 2192-2201
• 9 Carnicelli AP, Hong H, Connolly SJ. et al; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation 2022; 145 (04) 242-255
• 10 Little D, Chai-Adisaksopha C, Hillis C. et al. Resumption of anticoagulant therapy after anticoagulant-related gastrointestinal bleeding: a systematic review and meta-analysis. Thromb Res 2019; 175: 102-109
• 11 Ivany E, Lotto RR, Lip GYH, Lane DA. Managing uncertainty: physicians' decision making for stroke prevention for patients with atrial fibrillation and intracerebral hemorrhage. Thromb Haemost 2022; 122 (09) 1603-1611
• 12 Winijkul A, Kaewkumdee P, Yindeengam A, Lip GYH, Krittayaphong R. Clinical outcomes of patients with atrial fibrillation who survived from bleeding event: the results from COOL-AF Thailand registry. Thromb Haemost 2024; 124 (11) 991-1002
• 13 Karim N, Ho SY, Nicol E. et al. The left atrial appendage in humans: structure, physiology, and pathogenesis. Europace 2020; 22 (01) 5-18
• 14 Potpara T, Grygier M, Häusler KG. et al. Practical guide on left atrial appendage closure for the non-implanting physician: an international consensus paper. Europace 2024; 26 (04) euae035
• 15 Reddy VY, Doshi SK, Kar S. et al; PREVAIL and PROTECT AF Investigators. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017; 70 (24) 2964-2975
• 16 Osmancik P, Herman D, Neuzil P. et al; PRAGUE-17 Trial Investigators. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J Am Coll Cardiol 2022; 79 (01) 1-14
• 17 Turagam MK, Osmancik P, Neuzil P, Dukkipati SR, Reddy VY. Left atrial appendage closure versus oral anticoagulants in atrial fibrillation: a meta-analysis of randomized trials. J Am Coll Cardiol 2020; 76 (23) 2795-2797
• 18 Turagam MK, Kawamura I, Neuzil P. et al. Severity of ischemic stroke after left atrial appendage closure vs nonwarfarin oral anticoagulants. JACC Clin Electrophysiol 2023
• 19 Tzikas A, Shakir S, Gafoor S. et al. Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug. EuroIntervention 2016; 11 (10) 1170-1179
• 20 Hildick-Smith D, Landmesser U, Camm AJ. et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. Eur Heart J 2020; 41 (30) 2894-2901
• 21 Boersma LV, Ince H, Kische S. et al; EWOLUTION Investigators. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm 2017; 14 (09) 1302-1308
• 22 Freeman JV, Varosy P, Price MJ. et al. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol 2020; 75 (13) 1503-1518
• 23 Price MJ, Slotwiner D, Du C. et al. Clinical outcomes at 1 year following transcatheter left atrial appendage occlusion in the United States. JACC Cardiovasc Interv 2022; 15 (07) 741-750
• 24 Doshi SK, Kar S, Sadhu A. et al; PINNACLE FLX investigators [Link]. Two-year outcomes with a next-generation left atrial appendage device: final results of the PINNACLE FLX trial. J Am Heart Assoc 2023; 12 (04) e026295
• 25 Waranugraha Y, Lin LY, Tsai CT. Head-to-head comparison between left atrial appendage occlusion and non-vitamin K oral anticoagulants in non-valvular atrial fibrillation patients: a systematic review and meta-analysis study. Trends Cardiovasc Med 2023
• 26 Whitlock RP, Belley-Cote EP, Paparella D. et al; LAAOS III Investigators. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021; 384 (22) 2081-2091
• 27 Oliva A, Ioppolo AM, Chiarito M. et al. Left atrial appendage closure compared with oral anticoagulants for patients with atrial fibrillation: a systematic review and network meta-analysis. J Am Heart Assoc 2024; 13 (16) e034815
• 28 Bayer. A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People with Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke (OCEANIC-AF). 2022. Accessed at: https://classic.clinicaltrials.gov/show/NCT05643573
• 29 Anthos Therapeutics Inc., The TIMI Study Group. Laboratory Corporation of America. Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients with Atrial Fibrillation (AZALEA-TIMI 71). 2021. Accessed at: https://classic.clinicaltrials.gov/show/NCT04755283
• 30 Anthos Therapeutics Inc. Study to Evaluate the Efficacy and Safety of AbeLacimab in High-Risk Patients with Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation (LILAC-TIMI 76). 2022. Accessed at: https://classic.clinicaltrials.gov/show/NCT05712200
• 31 Janssen Research Development LLC. Bristol-Myers Squibb. A Study of Milvexian Versus Apixaban in Participants with Atrial Fibrillation (LIBREXIA-AF). 2023. Accessed at: https://classic.clinicaltrials.gov/show/NCT05757869
• 32 Piccini JP, Patel MR, Steffel J. et al; OCEANIC-AF Steering Committee and Investigators. Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med 2024 (e-pub ahead of print)
• 33 Boston Scientific Corporation. Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO). 2017. Accessed at: https://classic.clinicaltrials.gov/show/NCT02928497
• 34 Charite University Berlin Germany, Deutsches Zentrum für Herz-Kreislauf-Forschung, Atrial Fibrillation Network, Stiftung Institut fuer Herzinfarktforschung. Left Atrial Appendage CLOSURE in Patients with Atrial Fibrillation Compared to Medical Therapy (CLOSURE-AF). 2018. Accessed at: https://classic.clinicaltrials.gov/show/NCT03463317
• 35 Karolinska Institutet, Abbott Medical Devices. Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage. 2017. Accessed at: https://classic.clinicaltrials.gov/show/NCT02830152
• 36 Jena University Hospital. Comparison of LAA-Closure vs Oral Anticoagulation in Patients with NVAF and Status Post Intracranial Bleeding. 2020. Accessed at: https://classic.clinicaltrials.gov/show/NCT04298723
• 37 Huijboom M, Maarse M, Aarnink E. et al. COMPARE LAAO: rationale and design of the randomized controlled trial “COMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy.”. Am Heart J 2022; 250: 45-56
• 38 R&D Cardiologie, Research ZTNOfH, Development. Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy (COMPARE-LAAO). 2021. Accessed at: https://classic.clinicaltrials.gov/show/NCT04676880
• 39 Eitel I. Left Atrial Appendage Closure in Patients with Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease (LAA-KIDNEY). 2022. Accessed at: https://classic.clinicaltrials.gov/show/NCT05204212
• 40 Wazni OM, Boersma L, Healey JS. et al. Comparison of anticoagulation with left atrial appendage closure after atrial fibrillation ablation: rationale and design of the OPTION randomized trial. Am Heart J 2022; 251: 35-42
• 41 Boston Scientific Corporation. Comparison of Anticoagulation with Left Atrial Appendage Closure After AF Ablation (OPTION). 2019. Accessed at: https://classic.clinicaltrials.gov/show/NCT03795298
• 42 Kar S, Doshi SK, Alkhouli M. et al. Rationale and design of a randomized study comparing the Watchman FLX device to DOACs in patients with atrial fibrillation. Am Heart J 2023; 264: 123-132
• 43 Abbott Medical Devices. Amplatzer Amulet LAAO vs. NOAC (CATALYST). 2020. Accessed at: https://classic.clinicaltrials.gov/show/NCT04226547
• 44 University of Aarhus, Aarhus University Hospital, Aalborg University Hospital, Odense University Hospital, Sahlgrenska University Hospital Sweden, Karolinska University Hospital, et al. Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation (Occlusion-AF). 2019. Accessed at: https://classic.clinicaltrials.gov/show/NCT03642509
• 45 Korsholm K, Damgaard D, Valentin JB. et al. Left atrial appendage occlusion vs novel oral anticoagulation for stroke prevention in atrial fibrillation: rationale and design of the multicenter randomized occlusion-AF trial. Am Heart J 2022; 243: 28-38
• 46 Nielsen-Kudsk JE, Johnsen SP, Wester P. et al. Left atrial appendage occlusion versus standard medical care in patients with atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. EuroIntervention 2017; 13 (03) 371-378
• 47 Nielsen-Kudsk JE, Korsholm K, Damgaard D. et al. Clinical outcomes associated with left atrial appendage occlusion versus direct oral anticoagulation in atrial fibrillation. JACC Cardiovasc Interv 2021; 14 (01) 69-78
• 48 Chao TF, Joung B, Takahashi Y. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
• 49 Wang Y, Guo Y, Qin M. et al; Expert Reviewers. 2024 Chinese expert consensus guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost 2024; 124 (10) 897-911
• 50 Joglar JA, Chung MK, Armbruster AL. et al; Writing Committee Members. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2024; 83 (01) 109-279
• 51 Van Gelder IC, Rienstra M, Bunting KV. et al; ESC Scientific Document Group. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2024; 45 (36) 3314-3414
• 52 Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician's perspective. Thromb Haemost 2024
• 53 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the “Atrial Fibrillation Better Care” pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
• 54 Patel SM, Palazzolo MG, Murphy SA. et al. Evaluation of the atrial fibrillation better care pathway in the ENGAGE AF-TIMI 48 trial. Europace 2022; 24 (11) 1730-1738
• 55 Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive management with the ABC (Atrial Fibrillation Better Care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the AFFIRM trial. J Am Heart Assoc 2020; 9 (10) e014932
• 56 Shrestha B, Poudel B, Poudel D, Diaz Fraga J. National yearly trend of utilization and procedural complication of the Watchman device in the United States. Cureus 2022; 14 (06) e25567
• 57 Boriani G, Proietti M, Laroche C. et al; EORP-AF Long-Term General Registry Investigators. Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. Europace 2019; 21 (07) 1013-1022
• 58 Potpara TS, Dan GA, Trendafilova E. et al; BALKAN-AF Investigators. Stroke prevention in atrial fibrillation and “real world” adherence to guidelines in the Balkan Region: the BALKAN-AF survey. Sci Rep 2016; 6: 20432
• 59 Juhl Madsen O, Lamberts MK, Fosboel EL, Gislason G, Olesen JB, Strange JE. Trends in percutaneous left atrial appendage occlusion and 1-year mortality: a nationwide cohort study. Eur Heart J 2022; 43 (Suppl. 02) ehac544.2137
• 60 Lip GYH, Banerjee A, Boriani G. et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest 2018; 154 (05) 1121-1201
• 61 Brieger D, Amerena J, Attia J. et al; NHFA CSANZ Atrial Fibrillation Guideline Working Group. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018. Heart Lung Circ 2018; 27 (10) 1209-1266
• 62 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74 (01) 104-132
• 63 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
• 64 Andrade JG, Aguilar M, Atzema C. et al; Members of the Secondary Panel. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society comprehensive guidelines for the management of atrial fibrillation. Can J Cardiol 2020; 36 (12) 1847-1948
• 65 Saw J, Holmes DR, Cavalcante JL. et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. JACC Cardiovasc Interv 2023; 16 (11) 1384-1400
• 66 Glikson M, Wolff R, Hindricks G. et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. EuroIntervention 2020; 15 (13) 1133-1180
• 67 Tzikas A, Holmes Jr DR, Gafoor S. et al. Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. Europace 2017; 19 (01) 4-15
• 68 Anic A, Bakovic D, Jurisic Z. et al. Diagnostic and therapeutic pathways for the malignant left atrial appendage: European Heart Rhythm Association physician survey. Europace 2023; 25 (07) 25
• 69 Camm AJ. Leap or lag: left atrial appendage closure and guidelines. Europace 2023; 25 (05) 25
• 70 Glikson M, Wolff R, Hindricks G. et al; ESC Scientific Document Group. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion—an update. Europace 2020; 22 (02) 184
• 71 Teppo K, Airaksinen KEJ, Jaakkola J. et al. Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications. Eur Heart J 2024; 45 (20) 1819-1827
• 72 Nielsen PB, Brøndum RF, Nøhr AK, Overvad TF, Lip GYH. Risk of stroke in male and female patients with atrial fibrillation in a nationwide cohort. Nat Commun 2024; 15 (01) 6728
• 73 Teppo K, Lip GYH, Airaksinen KEJ. et al. Comparing CHA₂DS₂-VA and CHA₂DS₂-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur 2024; 43: 100967
• 74 Yoshimura H, Providencia R, Finan C, Schmidt AF, Lip GYH. Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?. Europace 2024; 26 (11) euae280
• 75 National Institute for Health and Clinical Excellence. Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. 2010; available at: https://www.nice.org.uk/guidance/ipg400/documents/thoracoscopic-exclusion-of-the-left-atrial-appendage-in-atrial-fibrillation-with-or-without-other-cardiac-surgery-for-the-prevention-of-thromboembolism-overview2
• 76 Di Biase L, Briceno DF, Trivedi C. et al. Is transesophageal echocardiogram mandatory in patients undergoing ablation of atrial fibrillation with uninterrupted novel oral anticoagulants? Results from a prospective multicenter registry. Heart Rhythm 2016; 13 (06) 1197-1202
• 77 Lee OH, Kim JS, Pak HN. et al. Feasibility of left atrial appendage occlusion for left atrial appendage thrombus in patients with persistent atrial fibrillation. Am J Cardiol 2018; 121 (12) 1534-1539
• 78 Korsholm K, Berti S, Iriart X. et al. Expert recommendations on cardiac computed tomography for planning transcatheter left atrial appendage occlusion. JACC Cardiovasc Interv 2020; 13 (03) 277-292
• 79 Osmancik P, Herman D, Linkova H, Hozman M, Labos M. A comparison of cardiac computed tomography, transesophageal and intracardiac echocardiography, and fluoroscopy for planning left atrial appendage closure. J Atr Fibrillation 2021; 13 (06) 20200449
• 80 Sharma PS, Padala SK, Gunda S, Koneru JN, Ellenbogen KA. Vascular complications during catheter ablation of cardiac arrhythmias: a comparison between vascular ultrasound guided access and conventional vascular access. J Cardiovasc Electrophysiol 2016; 27 (10) 1160-1166
• 81 Yamagata K, Wichterle D, Roubícek T. et al. Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-FAST trial). Europace 2018; 20 (07) 1107-1114
• 82 Sobolev M, Shiloh AL, Di Biase L, Slovut DP. Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis. Europace 2017; 19 (05) 850-855
• 83 Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization. Cochrane Database Syst Rev 2015; 1 (01) CD011447
• 84 Kupó P, Pap R, Sághy L. et al. Ultrasound guidance for femoral venous access in electrophysiology procedures—systematic review and meta-analysis. J Interv Card Electrophysiol 2020; 59 (02) 407-414
• 85 Delgado V, Ajmone Marsan N, de Waha S. et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J 2023; 44 (39) 3948-4042
• 86 Vizzari G, Grasso C, Sardone A. et al. Real-world experience with the new Watchman FLX device: data from two high-volume Sicilian centers. The FLX-iEST registry. Catheter Cardiovasc Interv 2022; 100 (01) 154-160
• 87 Price MJ, Friedman DJ, Du C. et al. Comparative safety of transcatheter LAAO with the first-generation Watchman and next-generation Watchman FLX devices. JACC Cardiovasc Interv 2022; 15 (21) 2115-2123
• 88 Paitazoglou C, Meincke F, Bergmann MW. et al. The ALSTER-FLX registry: 3-month outcomes after left atrial appendage occlusion using a next-generation device, a matched-pair analysis to EWOLUTION. Heart Rhythm 2022; 19 (06) 917-926
• 89 Lakkireddy D, Thaler D, Ellis CR. et al; Amulet IDE Investigators. Outcomes of the roll-in cohort of the Amulet IDE trial of left atrial appendage occlusion. Heart Rhythm O2 2022; 3 (05) 493-500
• 90 Chen S, Chun KRJ, Bordignon S. et al. Left atrial appendage occlusion using LAmbre Amulet and Watchman in atrial fibrillation. J Cardiol 2019; 73 (04) 299-306
• 91 Tilz RR, Fink T, Bartus K. et al. A collective European experience with left atrial appendage suture ligation using the LARIAT+ device. Europace 2020; 22 (06) 924-931
• 92 Betts TR, Grygier M, Nielsen Kudsk JE. et al; FLXibility investigators. Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility Post-Approval Study. Europace 2023; 25 (03) 914-921
• 93 Bhogal S, Aladin AI, Wermers JP, Morrison N, Gray N, Waksman R. Review of late-breaking trials from CRT 2022. Cardiovasc Revasc Med 2022; 40S: 3-7
• 94 Merdler I, Reddy PK, Bhogal S. et al. Review of late-breaking trials from CRT 2023. Cardiovasc Revasc Med 2023; 53S: S3-S9
• 95 Lakkireddy D, Thaler D, Ellis CR. et al. Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): a randomized, controlled trial. Circulation 2021; 144 (19) 1543-1552
• 96 Holmes DR, Reddy VY, Turi ZG. et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374 (9689): 534-542
• 97 Reddy VY, Doshi SK, Sievert H. et al; PROTECT AF Investigators. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 2013; 127 (06) 720-729
• 98 Bergmann MW, Betts TR, Sievert H. et al. Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry. EuroIntervention 2017; 13 (07) 877-884
• 99 Berti S, Pastormerlo LE, Rezzaghi M. et al. Left atrial appendage occlusion in high-risk patients with non-valvular atrial fibrillation. Heart 2016; 102 (24) 1969-1973
• 100 Korsholm K, Nielsen KM, Jensen JM, Jensen HK, Andersen G, Nielsen-Kudsk JE. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. EuroIntervention 2017; 12 (17) 2075-2082
• 101 Landmesser U, Schmidt B, Nielsen-Kudsk JE. et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention 2017; 13 (07) 867-876
• 102 Saw J, Tzikas A, Shakir S. et al. Incidence and clinical impact of device-associated thrombus and peri-device leak following left atrial appendage closure with the Amplatzer Cardiac Plug. JACC Cardiovasc Interv 2017; 10 (04) 391-399
• 103 Kar S, Doshi SK, Sadhu A. et al; PINNACLE FLX Investigators. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation 2021; 143 (18) 1754-1762
• 104 Ellis CR, Jackson GG, Kanagasundram AN. et al. Left atrial appendage closure in patients with prohibitive anatomy: insights from PINNACLE FLX. Heart Rhythm 2021; 18 (07) 1153-1161
• 105 Korsholm K, Samaras A, Andersen A, Jensen JM, Nielsen-Kudsk JE. The Watchman FLX device: first European experience and feasibility of intracardiac echocardiography to guide implantation. JACC Clin Electrophysiol 2020; 6 (13) 1633-1642
• 106 Paitazoglou C, Bergmann MW, Ince H. et al; theEWOLUTION Investigators. True efficacy of LAA closure: patient outcomes on long-term single-antiplatelet or no therapy: insights from the EWOLUTION registry. J Invasive Cardiol 2022; 34 (05) E348-E355
• 107 Simard T, Jung RG, Lehenbauer K. et al. Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J Am Coll Cardiol 2021; 78 (04) 297-313
• 108 Cepas-Guillén P, Flores-Umanzor E, Leduc N. et al. Impact of device implant depth after left atrial appendage occlusion. JACC Cardiovasc Interv 2023; 16 (17) 2139-2149
• 109 Saliba WI, Kawai K, Sato Y. et al. Enhanced thromboresistance and endothelialization of a novel fluoropolymer-coated left atrial appendage closure device. JACC Clin Electrophysiol 2023; 9 (8 Pt 2): 1555-1567
• 110 Lakkireddy D, Nielsen-Kudsk JE, Windecker S. et al. Mechanisms, predictors, and evolution of severe peri-device leaks with two different left atrial appendage occluders. Europace 2023; 25 (09) 25
• 111 Della Rocca DG, Murtaza G, Di Biase L. et al. Radiofrequency energy applications targeting significant residual leaks after Watchman implantation: a prospective, multicenter experience. JACC Clin Electrophysiol 2021; 7 (12) 1573-1584
• 112 Chen S, Weise FK, Chun KRJ, Schmidt B. Antithrombotic strategies after interventional left atrial appendage closure: an update. Expert Rev Cardiovasc Ther 2018; 16 (09) 675-678
• 113 Branca L, Tomasoni D, Cimino G. et al. Impact and predictors of device-related thrombus after percutaneous left atrial appendage closure. J Cardiovasc Med (Hagerstown) 2023; 24 (01) 12-19
• 114 Connolly S, Pogue J, Hart R. et al; ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367 (9526): 1903-1912
• 115 Connolly SJ, Eikelboom J, Joyner C. et al; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364 (09) 806-817
• 116 Mant J, Hobbs FD, Fletcher K. et al; BAFTA investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370 (9586): 493-503
• 117 Okumura K, Akao M, Yoshida T. et al; ELDERCARE-AF Committees and Investigators. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020; 383 (18) 1735-1745
• 118 Riegler L, Palermi S, Scarafile R. et al. Clinical and multi-modality imaging approach in the selection of patients for left atrial appendage closure. Rev Cardiovasc Med 2021; 22 (04) 1197-1204
• 119 Søndergaard L, Wong YH, Reddy VY. et al. Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN. JACC Cardiovasc Interv 2019; 12 (11) 1055-1063
• 120 Cruz-González I, Trejo-Velasco B. Percutaneous left atrial appendage occlusion in the current practice. Kardiol Pol 2021; 79 (03) 255-268
• 121 Ledwoch J, Sievert K, Boersma LVA. et al; EWOLUTION Investigators. Initial and long-term antithrombotic therapy after left atrial appendage closure with the WATCHMAN. Europace 2020; 22 (07) 1036-1043
• 122 Freeman JV, Higgins AY, Wang Y. et al. Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation. J Am Coll Cardiol 2022; 79 (18) 1785-1798
• 123 Freeman J, Hsu JC, Kapadia S. et al. Ce-452771–4 outcomes with different postprocedural antithrombotic therapy regimens following left atrial appendage occlusion. Heart Rhythm 2023; 20: S36-S37
• 124 Carvalho PEP, Gewehr DM, Miyawaki IA. et al. Comparison of initial antithrombotic regimens after left atrial appendage occlusion: a systematic review and network meta-analysis. J Am Coll Cardiol 2023; 82 (18) 1765-1773
• 125 Mhanna M, Beran A, Al-Abdouh A. et al. Single versus dual antiplatelet therapy following left atrial appendage occlusion in patients with high bleeding risk. Curr Probl Cardiol 2022; 47 (09) 101269
• 126 Vignali L, Gurgoglione FL, Barocelli F. et al. Looking for optimal antithrombotic strategy after transcatheter left atrial appendage occlusion: a real-world comparison of different antiplatelet regimens. Int J Cardiol 2023; 371: 92-99
• 127 Rodriguez-Gabella T, Nombela-Franco L, Regueiro A. et al. Single antiplatelet therapy following left atrial appendage closure in patients with contraindication to anticoagulation. J Am Coll Cardiol 2016; 68 (17) 1920-1921
• 128 Azienda Ospedaliero Universitaria Maggiore della Carita, Abbott Medical Devices. Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: A Multicenter, Randomized Study (ARMYDA-AMULET). 2021. Accessed at: https://classic.clinicaltrials.gov/show/NCT05554822
• 129 Cepas-Guillen PL, Flores-Umanzor E, Regueiro A. et al. Low dose of direct oral anticoagulants after left atrial appendage occlusion. J Cardiovasc Dev Dis 2021; 8 (11) 8
• 130 Della Rocca DG, Magnocavallo M, Di Biase L. et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc Interv 2021; 14 (21) 2353-2364
• 131 Freixa X. Apixaban vs Dual Antiplatet Therapy Study After Left Atrial Appendage Occlosure (ADALA). 2019 Accessed at: https://classic.clinicaltrials.gov/show/NCT05632445
• 132 Freixa X, Cruz-González I, Cepas-Guillén P. et al. Low dose direct oral anticoagulation vs. DAPT after LAAO. Euro PCR 2023
• 133 Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Institut universitaire de cardiologie et de pneumologie de Québec University Laval. Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (ANDES). 2018. Accessed at: https://classic.clinicaltrials.gov/show/NCT03568890
• 134 Schmidt B, Nielsen-Kudsk JE, Ellis CR. et al. Incidence, predictors, and clinical outcomes of device-related thrombus in the Amulet IDE trial. JACC Clin Electrophysiol 2023; 9 (01) 96-107
• 135 Dukkipati SR, Kar S, Holmes DR. et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation 2018; 138 (09) 874-885
• 136 Dukkipati SR, Holmes Jr DR, Doshi SK. et al. Impact of peridevice leak on 5-year outcomes after left atrial appendage closure. J Am Coll Cardiol 2022; 80 (05) 469-483
• 137 Alkhouli M, Du C, Killu A. et al. Clinical impact of residual leaks following left atrial appendage occlusion: insights from the NCDR LAAO registry. JACC Clin Electrophysiol 2022; 8 (06) 766-778
• 138 Sharma SP, Turagam MK, Gopinathannair R. et al. Direct current cardioversion of atrial fibrillation in patients with left atrial appendage occlusion devices. J Am Coll Cardiol 2019; 74 (18) 2267-2274
• 139 Maarse M, Wintgens LIS, Ponomarenko A. et al. Impact of anticoagulation strategy after left atrial appendage occlusion in patients requiring direct current cardioversion. J Cardiovasc Electrophysiol 2021; 32 (03) 737-744
• 140 Joglar JA, Chung MK, Armbruster AL. et al. ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2024; 149 (01) e1-e156